HPV vaccine : can we afford to hesitate?

Richter, Karin Louise; Dreyer, Greta; Lindeque, B. Gerhard; Botha, M.H.

dc.contributor.author	Richter, Karin Louise
dc.contributor.author	Dreyer, Greta
dc.contributor.author	Lindeque, B. Gerhard
dc.contributor.author	Botha, M.H.
dc.date.accessioned	2015-05-20T09:04:14Z
dc.date.available	2015-05-20T09:04:14Z
dc.date.issued	2014-08
dc.description.abstract	Cervical cancer, caused by human papillomavirus (HPV) infection, is highly prevalent in sub-Saharan Africa. The estimated annual incidence of cervical cancer is 35/100 000 women, with 22.5/100 000 associated deaths. This is in stark contrast to the 6.6/100 000 cases and 2.7/100 000 deaths reported in developed countries such as the USA, where HPV vaccination has been available since 2006.	en_ZA
dc.description.librarian	am2015	en_ZA
dc.description.uri	http://www.samj.org.za	en_ZA
dc.identifier.citation	Richter, KL, Dreyer, G, Lindeque, BG & Botha, MH 2014, 'HPV vaccine : can we afford to hesitate?', South African Medical Journal, vol. 104, no. 8, pp. 522-523.	en_ZA
dc.identifier.issn	0256-9574 (print)
dc.identifier.issn	2078-5135 (online)
dc.identifier.other	10.7196/SAMJ.8449
dc.identifier.uri	http://hdl.handle.net/2263/45190
dc.language.iso	en	en_ZA
dc.publisher	Health and Medical Publishing Group	en_ZA
dc.rights	© 2014 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0).	en_ZA
dc.subject	Cervical canver	en_ZA
dc.subject	HPV vaccine	en_ZA
dc.subject	Human papillomavirus (HPV)	en_ZA
dc.subject	Vaccination	en_ZA
dc.title	HPV vaccine : can we afford to hesitate?	en_ZA
dc.type	Article	en_ZA